Haleon PLC closed 5.73% below its 52-week high of £4.01, which the company reached on September 18th.

Shares of Haleon PLC HLN inched down 0.91% to £3.72 Friday, on what proved to be an all-around grim trading session for the ...

The UK-based pharmaceutical company Haleon will invest $54.2 million to upgrade its R&D facility in Richmond, which has helped birth or grow products such as Advil, Emergen-C and Robitussin.

Haleon, an international manufacturer of medicine, vitamins and toothpaste, will upgrade its lab in Richmond's North Side at a cost of $54 million, the company announced Monday. Based in England ...

Pfizer (PFE) announces that it intends to sell approximately 700M ordinary shares in Haleon plc (HLN), representing approximately 7.7% of Haleon’s issued share capital. “There will be no sale ...

Bernstein downgraded Haleon (HLN) to Market Perform from Outperform. Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for ...

Once complete, Pfizer's stake in Haleon will fall from 15.0% to around 7.3%. Pfizer's move comes after Haleon's spin-off as an independent consumer healthcare company, part of plans to reshape its ...

Once complete, Pfizer's stake in Haleon will fall from 15.0% to around 7.3%. Pfizer's move comes after Haleon's spin-off as an independent consumer healthcare company, part of plans to reshape its ...

To calculate this metric for Haleon, this is the formula: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.09 = UK£2.5b ÷ (UK£33b - UK£5.6b ...

Pfizer has sold 700 million shares in British consumer-healthcare business Haleon for 2.50 billion pounds, equivalent to US$3.05 billion, it said in a statement. The U.S. drugmaker said Wednesday ...

NEW YORK, Jan. 14 (Xinhua) -- Pfizer Inc., the American multinational pharmaceutical and biotechnology corporation, is offering around 700 million shares in Haleon Plc, representing a roughly 7.7 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...